Skip to main content
Premium Trial:

Request an Annual Quote

Agendia, Erasmus Medical Center, Invitrogen, Affy, Sigma-Aldrich, University of Leicester, Agilent, Cogenics

Premium

Agendia Licenses Genetic Profile for Tamoxifen Resistance from Erasmus Medical Center

Agendia said this week that it has signed a license agreement with the Erasmus University Medical Center in Rotterdam, the Netherlands, giving it exclusive rights to a genetic profile that predicts resistance to tamoxifen.

Agendia said it will validate the tamoxifen profile in collaboration with the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital.

Once validated, the company intends to add the profile to its MammaPrint gene expression-based breast cancer recurrence test.

In addition to the license agreement, the three organizations have entered a research collaboration focused on "next-generation hormonal therapies for breast cancer," Agendia said.

Financial terms of the agreement were not disclosed.


Invitrogen, Affy, Sigma-Aldrich, Others Occupy New Nasdaq Tier

Shares of Qiagen, Affymetrix, Invitrogen, Molecular Devices, Serologicals, and Sigma-Aldrich have been listed on the Nasdaq Global Select Market, a new market tier for a set of high-performing companies, according to the Nasdaq web site.

On Feb. 15 Nasdaq said it would rename its National Market to Nasdaq Global Market and create a Nasdaq Global Select Market with the highest initial listing standards of any exchange in the world.

Under the change, companies listed on the exchange will be classified under three listing tiers: Nasdaq Global Select Market, Nasdaq Global Market, and Nasdaq Capital Market. Nasdaq said it plans to launch indexes based on these new tiers.


University of Leicester Picks Up Two of Febit's Geniom Systems

The University of Leicester has purchased two Geniom systems from Febit Biotech, according to the company.

The German array company said that the sale to Leicester will help grow its presence in the UK market. According to Febit, the Oxford-based Wellcome Trust Center for Human Genetics also has a Geniom system installed.

Febit said that the first Geniom system was set up in Leicester in June, and that the second system would be installed in late summer. The university will use the system for gene expression and SNP analysis, Febit said.


Agilent Recertifies Cogenics for Microarray Services

Agilent Technologies recertified Cogenics, a division of Clinical Data, as a microarray service provider for its gene-expression microarrays, the companies said last week.

Agilent also extended the certification to include its array-based comparative genomic hybridization experiments.

Cogenics passed a set of assessments that included proficiency in analyzing Agilent 60-mer oligo microarrays using the complete Agilent system; sample quality control using the Agilent 2100 Bioanalyzer; sample labeling using Agilent reagents and protocols; hybridization using SureHyb chambers; microarray analysis using the Agilent scanner and feature extraction software; and final data-analysis using the GeneSpring bioinformatics platform.

Cogenics has earned certification for the past three years.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.